Feline Aortic Stenosis and Subaortic Stenosis

Feline aortic stenosis (AS) and subaortic stenosis (SAS) are congenital or, rarely, acquired obstructive lesions of the left ventricular outflow tract (LVOT) or the aortic valve itself, resulting in fixed obstruction to systolic blood ejection from the left ventricle. These conditions are uncommon in cats compared to dogs and are distinct from the dynamic LVOT obstruction that can occur secondary to hypertrophic cardiomyopathy (HCM) [1][2]. The fixed obstruction forces the left ventricle to generate markedly elevated pressures to maintain forward cardiac output, leading to concentric left ventricular hypertrophy and, ultimately, myocardial dysfunction [2]. Because the referral literature on feline congenital cardiac disease is sparse relative to HCM, much of what is known is extrapolated from canine SAS data and from case series of cats with congenital heart disease.

Etiology

Aortic stenosis and subaortic stenosis in cats are predominantly congenital lesions, arising from abnormal embryological development of the cardiac outflow tract. Three anatomical subtypes are recognized by analogy with canine and human disease:

1. ·Valvular aortic stenosis — malformation of the aortic valve leaflets themselves (most commonly bicuspid aortic valve or leaflet fusion), creating a fixed obstruction at the valve level.
2. ·Subvalvular (subaortic) stenosis — a fibrous or fibromuscular ridge or ring located just below the aortic valve in the LVOT; this is the form most commonly reported in dogs and is presumed to be the most frequent form in cats as well.
3. ·Supravalvular aortic stenosis — a fibrous membrane or hypoplastic segment above the aortic valve; the rarest form.

A hereditary basis has been established in dogs (particularly Newfoundlands and Golden Retrievers), but specific genetic studies in cats are lacking. Some cases in cats may occur sporadically or as part of broader congenital cardiac defect syndromes.

Pathophysiological Mechanism

The hallmark consequence of fixed LVOT obstruction is pressure-overload left ventricular hypertrophy. Because the left ventricle must generate supranormal systolic pressures to propel blood across the obstruction, the myocardium hypertrophies concentrically (wall thickening without chamber dilation) in an attempt to normalize wall stress (by the law of Laplace) [1][2]. This process is morphologically similar to, but mechanistically distinct from, HCM [1]. Key downstream effects include:

• ·Diastolic dysfunction — the hypertrophied, stiff ventricle relaxes abnormally, raising left atrial and pulmonary venous pressures, predisposing to pulmonary edema and pleural effusion [2].
• ·Myocardial ischemia — increased oxygen demand from hypertrophied myocardium combined with reduced coronary perfusion pressure distal to the obstruction leads to subendocardial ischemia, which can trigger ventricular arrhythmias.
• ·Reduced stroke volume and cardiac output — in severe or decompensated cases, the ventricle cannot generate sufficient pressure to overcome the obstruction at higher heart rates or during exercise.
• ·Poststenotic aortic dilation — turbulent jet flow through the stenotic region causes dilation of the ascending aorta distal to the obstruction.
• ·Endocarditis risk — turbulent flow and endothelial injury at and distal to the stenosis increase susceptibility to infective endocarditis of the aortic valve.

The severity of obstruction is quantified by the peak systolic pressure gradient across the stenosis (measured by Doppler echocardiography). Gradients are generally classified as mild (<40 mmHg), moderate (40–80 mmHg), or severe (>80 mmHg), though exact thresholds may vary among institutions [2].

Physical Examination

A loud, harsh, left-basilar (pulmonic/aortic area) systolic ejection murmur is the most consistent finding. The murmur may radiate cranially toward the thoracic inlet/carotid arteries. Femoral pulses may exhibit a slow rise and reduced amplitude ("pulsus parvus et tardus") in severe cases. Concurrent findings of tachypnea, increased respiratory effort, or a gallop sound suggest heart failure [2].

Echocardiography (Definitive Diagnosis)

Two-dimensional and Doppler echocardiography are the cornerstone diagnostic tools:

• ·2D and M-mode imaging: Identification of the anatomical site of obstruction (subvalvular fibromuscular ridge, valve leaflet abnormality, or supravalvular membrane); concentric left ventricular hypertrophy; poststenotic aortic dilation; left atrial size assessment [1][2].
• ·Continuous-wave (CW) Doppler: Measurement of peak blood flow velocity across the stenosis, from which the peak instantaneous pressure gradient is calculated using the modified Bernoulli equation (ΔP = 4v²). This is the primary method for quantifying severity [2].
• ·Color-flow Doppler: Visualization of turbulent, aliased flow at the obstruction site; helps localize the level of stenosis.
• ·Spectral Doppler of pulmonary venous flow and mitral inflow: Assessment of diastolic function and filling pressures [2].

Electrocardiography (ECG)

ECG may reveal left ventricular enlargement patterns (tall R waves in lead II), ST-segment changes suggestive of myocardial ischemia, or ventricular arrhythmias (premature ventricular complexes, ventricular tachycardia). Holter (24-hour ambulatory ECG) monitoring is advisable in cats with syncopal episodes to document arrhythmias.

Thoracic Radiography

Radiographs may show left-sided cardiomegaly, left atrial enlargement, poststenotic aortic dilation (a focal bulge at the aortic root), and pulmonary venous congestion or pulmonary edema if CHF is present [2].

Laboratory Evaluation

Although no laboratory test is specific for AS/SAS, the following parameters are clinically relevant in affected cats:

• ·Complete Blood Count (CBC):
  • ·Hematocrit (HCT): May be elevated (stress erythrocytosis/hemoconcentration) or reduced (anemia of chronic disease in advanced cardiac disease). Monitoring baseline is important.
  • ·Platelet count (PLT): Thrombocytopenia can occur secondary to turbulent-flow–induced platelet activation/consumption or if concurrent arterial thromboembolism develops.
• ·Serum Biochemistry:
  • ·Blood Urea Nitrogen (BUN) and Creatinine (CREA): Elevated in cats with reduced cardiac output and prerenal azotemia; critical before initiating diuretic therapy to assess renal reserve [2].
  • ·Alanine Aminotransferase (ALT): Mildly elevated hepatic enzymes may reflect hepatic venous congestion in right heart failure.
  • ·Total Bilirubin (TBIL): Can be mildly elevated in severe congestion.
  • ·Albumin (ALB): Hypoalbuminemia may develop in chronic heart failure due to hepatic congestion, decreased synthesis, or protein-losing enteropathy.
  • ·Globulins (GLOB): Generally non-specific but monitored as part of overall protein status.
• ·Cardiac Biomarkers:
  • ·NT-proBNP (N-terminal pro-B-type natriuretic peptide): Elevated in cats with significant pressure overload or CHF; useful as a screening and monitoring tool [2].
  • ·Cardiac Troponin I (cTnI): Elevation indicates myocardial injury/ischemia, which may occur secondary to severe pressure overload.
• ·Blood Pressure (Systemic Arterial): Hypertension can exacerbate LVOT obstruction and must be excluded or treated as a concurrent condition.

Cardiac Catheterization

Rarely performed in cats due to the diagnostic accuracy of echocardiography, but direct pressure gradient measurement across the stenosis during catheterization remains the gold standard reference method.

Management of feline AS/SAS is guided by the severity of obstruction, presence of symptoms, and secondary complications (CHF, arrhythmias). There is no curative medical therapy; treatment is aimed at reducing clinical signs, preventing complications, and improving quality of life.

Mild Disease (Gradient <40 mmHg, Asymptomatic)

• ·Activity restriction: Avoidance of strenuous exercise and excitement to minimize arrhythmia risk and syncope.
• ·Periodic monitoring: Echocardiography every 6–12 months to reassess gradient and ventricular morphology.
• ·No routine pharmacotherapy is generally indicated in asymptomatic mild cases.

Moderate-to-Severe Disease (Gradient ≥40 mmHg)

Beta-adrenergic blockers (e.g., atenolol, 6.25–12.5 mg/cat PO q12–24h):

• ·Reduce heart rate, prolonging diastolic filling time and reducing myocardial oxygen demand.
• ·Decrease the likelihood of exercise-induced arrhythmias.
• ·May attenuate dynamic components that sometimes coexist with fixed obstruction.
• ·By analogy with canine SAS management, beta-blockers are the most commonly recommended medical intervention, though controlled feline-specific data are lacking.

Congestive Heart Failure (CHF)

When CHF with pulmonary edema or pleural effusion develops [2]:

• ·Furosemide (loop diuretic): Acute intravenous dosing (1–2 mg/kg IV/IM q1–4h as needed) for acute decompensation; transition to oral maintenance (1–2 mg/kg PO q12–24h) once stabilized.
• ·Thoracocentesis: For cats presenting with significant pleural effusion causing dyspnea.
• ·Oxygen supplementation: Low-stress oxygen cage during acute decompensation.
• ·Pimobendan: Use is controversial in fixed outflow tract obstruction (as opposed to dilated or low-output cardiomyopathy). In HCM with CHF, some evidence supports its use [8], but in cats with predominant fixed obstruction, the positive inotropic effect of pimobendan could theoretically worsen the gradient by increasing contractility; use requires careful case-by-case evaluation [8].
• ·ACE inhibitors (e.g., benazepril, enalapril): May be considered for afterload reduction in cats with concurrent systemic hypertension or progressive left atrial enlargement; evidence in fixed LVOT obstruction is limited.

Arrhythmia Management

• ·Ventricular arrhythmias (premature ventricular complexes, ventricular tachycardia): Beta-blockers are first-line.
• ·Sotalol or mexiletine may be considered in refractory ventricular arrhythmias under specialist guidance.

Interventional / Surgical Options

• ·Balloon valvuloplasty (percutaneous balloon dilation): An established palliative procedure in dogs with valvular pulmonic stenosis; its role in feline aortic or subaortic stenosis is very limited and largely experimental. Balloon dilation of discrete subaortic membranes has been performed in dogs with variable success.
• ·Surgical resection of subaortic membranes has been reported in dogs; feasibility and outcomes in cats are poorly documented.
• ·Given the small patient size of cats and limited reported experience, interventional procedures are not currently considered standard of care in feline AS/SAS.

Thromboprophylaxis

• ·Cats with left atrial enlargement are at risk for aortic thromboembolism (ATE) [5].
• ·Clopidogrel (18.75 mg/cat PO q24h) is the preferred antiplatelet agent for primary ATE prevention in cats with cardiac disease and LA enlargement [2][5].
• ·Low-dose aspirin may be used as an alternative or adjunct.

Formal peer-reviewed survival statistics specific to feline aortic stenosis and subaortic stenosis are not available in the references cited above, and the condition is sufficiently rare in cats that large prospective outcome studies have not been published. The following prognostic framework is therefore based on pathophysiological principles, limited case series, and extrapolation from better-characterized diseases:

Severity-Dependent Prognosis

• ·Mild AS/SAS (gradient <40 mmHg): Cats may survive for many years with near-normal life expectancy if obstruction does not progress and arrhythmias are absent. Quality of life is generally good.
• ·Moderate AS/SAS (gradient 40–80 mmHg): Intermediate prognosis. Risk of arrhythmia-related syncope and sudden death increases; onset of CHF worsens outlook.
• ·Severe AS/SAS (gradient >80 mmHg): Guarded to poor prognosis. High risk of sudden death (ventricular fibrillation secondary to ischemia-triggered arrhythmia), early CHF, and progressive ventricular dysfunction.

Key Negative Prognostic Indicators (by extrapolation from feline cardiomyopathy literature and canine SAS data):

• ·Left atrial enlargement — strongly associated with worse outcomes in cats with left-sided cardiac disease [5]
• ·Development of CHF — significantly worsens short- and long-term survival [5]
• ·Aortic thromboembolism — a catastrophic complication carrying high acute mortality [5]
• ·Presence of ventricular arrhythmias on Holter monitoring
• ·Severely reduced left ventricular systolic function (low fractional shortening)

In feline HCM (a distinct but related hypertrophic condition), median survival after diagnosis of CHF has been reported in the range of months to a few years, with left atrial size being the strongest echocardiographic predictor of outcome [5]. Whether similar metrics apply directly to fixed LVOT obstruction in cats is uncertain, but the underlying hemodynamic burden of pressure overload and CHF is comparable.

Data on long-term prognosis specific to feline AS/SAS is limited in current veterinary literature; no peer-reviewed survival statistics specifically for this condition were identified in the references cited above. Owners should be counseled that sudden death can occur without warning even in apparently compensated cats, particularly those with severe obstruction.

Genetic and Breeding Considerations

• ·Since AS/SAS in cats is predominantly congenital, the most meaningful preventive measure is responsible breeding. Cats diagnosed with aortic or subaortic stenosis should not be used for breeding, as a hereditary component is suspected based on findings in related species.
• ·Breeders of pedigree cats should pursue cardiac auscultation and echocardiographic screening of breeding stock, ideally by a board-certified veterinary cardiologist, before breeding.

No Vaccine Exists

There is no preventive vaccine for AS/SAS, as this is a structural/developmental disease, not an infectious one.

Prenatal / Developmental Factors

• ·Avoiding teratogenic drugs, toxins, or infections during pregnancy may reduce the overall risk of congenital cardiac defects, though specific causal agents for feline AS/SAS have not been identified.

Early Detection

• ·Routine cardiac auscultation at every wellness examination enables early detection of heart murmurs in young kittens. Identification of a murmur should prompt echocardiographic referral, as early characterization of lesion severity guides management and owner counseling.
• ·Echocardiographic screening of littermates and first-degree relatives of affected individuals is advisable [2].

Management of Known Cases

• ·Avoiding extreme physical exertion and stressful situations reduces arrhythmia risk in known affected cats.
• ·Maintaining a low-sodium diet and optimal body condition reduces cardiac workload.